Clinical trials: Covid-19 Patients
COVID-19
Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
This open label, randomized, controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in COVID-19 subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate…
- Trial name
- NCT04573153
- Testing
- Hydroxychloroquine + Metabolic cofactor supplementation, Hydroxychloroquine + Sorbitol
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- ScandiBio Therapeutics AB
COVID-19
Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19
This is a double-blind, multicentre, multinational study to evaluate the safety and collect preliminary efficacy data of Codivir drug product in 130 hospitalized adults with moderate COVID-19 symptoms.
- Trial name
- NCT05218356
- Testing
- Covidir injections, Quantitative PCR SARS-CoV-2, IgM and IgG dosage
- Where
- 5 sites in Brazil
- Volunteers
- 130 people
- Sponsor
- Code Pharma
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
COVID-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (500 mg/ 5 days) to treat moderate to severe COVID-19 pneumonia.
- Trial name
- NCT04329572
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 400 people
- Sponsor
- Azidus Brasil
Post-acute COVID-19 Syndrome
SENSING-AI Cohort for Long COVID Patients
The prospective study will focus on the collection of biometric and psychometric data from a limited population for 1 month with the aim of complementing the SENSING-AI retrospective cohort.
- Trial name
- SENSING-AI (NCT05204615)
- Testing
- Collection of clinical, psychometric and biometric data
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Adhera Health, Inc.
Hypertension, Hypoxia
The VISION-Acute Study
AIM: We propose an innovative approach using Lifelight® smart technology that will enable the continued provision of high level patient care at the same time as reducing pressure on nursing and equipment resources.
- Conditions
- Hypertension, Hypoxia, Hypotension
- Trial name
- NCT04589923
- Testing
- Lifelight® Data Collect Blood Pressure Group, Lifelight® Data Collect Oxygen Saturation Group
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- Xim Limited
Severe Acute Respiratory Syndrome Coronavirus 2
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.
- Trial name
- COVID-19 (NCT04522986)
- Testing
- Mesenchymal stem cell
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
Covid-19, SARS-CoV2
Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients
The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in participants with SARS-CoV-2 pneumonia.
- Trial name
- COVA (NCT04472728)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 238 people
- Sponsor
- Biophytis
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy.
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral
- Trial name
- NCT05123755
- Testing
- AV-001 Injection
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vasomune Therapeutics, Inc.
COVID-19
Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients
The aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.
- Trial name
- NCT04352465
- Testing
- Methotrexate
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Azidus Brasil
Covid19
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.
- Trial name
- NCT04604678
- Testing
- Metformin, Naltrexone
- Where
- United States
- Sponsor
- AgelessRx
Covid19
A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19
This study aims to investigate the potential antiviral efficacy and safety of a novel formulation of Niclosamide; a well-known antihelmintic agent, together with an established COVID-19 treatment regimen in patients.
- Trial name
- NICLONEX (NCT04558021)
- Testing
- Niclosamide suspension
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Imuneks Farma ilac San. Tic. A.S.
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-US-I (NCT04442178)
- Testing
- CYT107
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Revimmune
COVID-19, ARDS
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
COVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a dysregulated immune response.
- Trial name
- NCT04401475
- Testing
- SOC plus 15mg/kg EB05 IV
- Where
- 20 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Edesa Biotech Inc.
Covid19
Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.
This is a phase I/II study with Amorphous Calcium Carbonate (ACC) administered sublingual and in Inhalation concomitantly with BAT (Best Available Care) as Compared to Placebo and BAT for the treatment of Moderate to Severe…
- Trial name
- NCT04900337
- Testing
- AMOR 18 Powder & Inhalation
- Where
- 3 sites in Israel
- Volunteers
- 66 people
- Sponsor
- Amorphical Ltd.
Confirmed Coronavirus Disease
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e.
- Trial name
- NCT04530136
- Testing
- Ruconest
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pharming Technologies B.V.
COVID-19, Oscillation and Lung Expansion
Oscillation and Lung Expansion Therapy in Patients With COVID-19
A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19
- Trial name
- NCT04582214
- Testing
- MetaNeb® System
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hill-Rom
COVID-19 Infection
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection
An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection
- Trial name
- NCT04374032
- Testing
- metenkefalin + tridecactide, The standard of care
- Where
- 5 sites in Bosnia and Herzegovina
- Volunteers
- 120 people
- Sponsor
- Bosnalijek D.D
COVID-19 Respiratory Infection, Viral Pneumonia
Study of the Use of the Drug Ingaron in Patients With COVID-19
Interferon gamma is a powerful endogenous regulatory cytokine that activates the antiviral immune response, while it also has its own antiviral activity.
- Trial name
- NCT05386459
- Testing
- Interferon Gamma
- Where
- Russia
- Volunteers
- 36 people
- Sponsor
- SPP Pharmaclon Ltd.
ARDS, Human, Covid-19
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19
This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days…
- Trial name
- NCT04456361
- Testing
- Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords
- Where
- Mexico
- Volunteers
- 9 people
- Sponsor
- Instituto de Medicina Regenerativa